[Multiple myeloma and autologous haematopoietic stem-cell transplantation without cryopreservation: experiences of the Clinical Hematology Department of Casablanca, Morocco]

Salma Fares, Halima Hadri, Mohamed Rachid, Tarik Moutiqui, Bouchra Oukkache, Asmaa Quessar, Salma Fares, Halima Hadri, Mohamed Rachid, Tarik Moutiqui, Bouchra Oukkache, Asmaa Quessar

Abstract

High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) is the gold standard treatment for multiple myeloma in subjects aged ≤ 65 years. In developing countries, AHSCT without cryopreservation reduces the costs of hospitalization and all necessary equipments. We conducted a longitudinal, prospective, open study to evaluate this procedure at the Department of Clinical Hematology, Casablanca, Morocco. Data from the medical records of 64 patients were collected over a period of 24 months. After induction therapy, the overall response (complete remission + very good partial response) was 67.2% (43 patients). The mean CD34-cell count in the autograft was 12.97*106 /kg [2.4- 53*106 Cd34+/kg] and the median length of hospitalization was 20.5 days [14-60 days]. The overall response after autograf was 84% (54 patients). At 24 months follow-up, overall survival (OS) was 83.5%, median OS was not reached and progression-free survival (PFS) was 65.9%, with a median PFS of 24.1 months with 95% confidence interval [21.7-26.5 months]. Autologous hematopoietic stem cell transplantation without cryopreservation is an excellent alternative in our context reducing wait times and freezing costs.

Keywords: Multiple myeloma; autologous; haematopoietic stem-cell transplantation; without cryopreservation.

Conflict of interest statement

Les auteurs ne déclarent aucun conflit d´intérêts.

Copyright: Salma Fares et al.

Figures

Figure 1
Figure 1
évaluation de la réponse thérapeutique des patients suivis pour myélome multiple à J100 en post-autogreffe des cellules souches hématopoïétiques
Figure 2
Figure 2
survie globale estimée des patients suivis pour myélome multiple ayant bénéficié d´une autogreffe des cellules souches hématopoïétiques sans cryoconservation
Figure 3
Figure 3
survie sans progression des patients suivis pour myélome multiple ayant bénéficié d´une autogreffe des cellules souches hématopoïétiques sans cryoconservation

References

    1. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review. 1975-2007. Consulté le 10/03/2019.
    1. Registre des Cancers de la Région du Grand Casablanca 2004 Volume 2: Epidémiologie-Situation et actions. Consulté le 12/02/2019.
    1. Moreau P, Avet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011 May 10;29(14):1898–906.
    1. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 9;117(23):6063–73.
    1. Wannesson L, Panzarella T, Mikhael J, Keating A. Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Ann Oncol. 2007 Apr;18(4):623–632.
    1. Cuellar-Ambrosi F, Karduss UA, Gomez WR, Mondragon MC, Velasquez-Lopera M, Calle S. Hematologic reconstitution following high-dose and supralethal chemoradiotherapy using stored, noncryopreserved autologous hematopoietic stem cells. Transplant Proc. 2004;36:1704–1705.
    1. Ruiz-Arguelles GJ, Gomez-Rangel D, Ruiz-Delgado GJ, Ruiz-Argüelles A, Beatriz Pérez-Romano B, Rivadeneyra L. Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: a single-institution, 10-year experience. Acta Haematol. 2003;110(4):179–83.
    1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48.
    1. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International Staging System for Multiple Myeloma. J Clin Oncol. 2005;23:3412–20.
    1. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716–30.
    1. Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, et al. High dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma. Biol Blood Marrow Transplant. 2007 Feb;13(2):183–96.
    1. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma. Blood. 1998 Nov 1;92(9):3131–6.
    1. Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, et al. Achieving at least very good partial remission is a simple and robust prognostic factor in a patient with multiple myeloma treated with high dose therapy. J Clin Oncol. 2009 Dec 1;27(34):5720–6.
    1. Ramzi M, Zakerinia M, Nourani H, Dehghani M, Vojdani R, Haghighinejad H, et al. Non-cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. Clin Transplant. 2012 Jan-Feb;26(1):117–22.
    1. Kayal S, Sharma A, Iqbal S, Tejomurtula T, Cyriac SL, Raina V. High dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at all India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Clinical Lymphoma Myeloma & Leukemia. 2014 Apr;14(2):140–7.
    1. Bekadja MA, Brahimi M, Osmani S, Arabi A, Bouhass R, Yafour N, et al. A simplified method for autologous stem cell transplantation in multiple myeloma. Hematol Oncol Stem Cell Ther. 2012;5(1):49–53.
    1. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant. 2009;44:715–9.
    1. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, et al. Autologous stem cell transplantation in multiple myeloma: improved survival in non secretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen: asingle-centre experience in 127 patients. Bone Marrow Transplant. 2003 Feb;31(3):163–70.
    1. Kumar L, Ghosh J, Ganessan P, Gupta A, Hariprasad R, Kochupillai V, et al. High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. Bone Marrow Transplant. 2009 Mar;43(6):481–9.
    1. Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L, et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant. 2005 Jan;35(2):159–64.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner